{"entity":{"id":"nct06265428","kind":"trial","name":"A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer","aka":[],"tldr":"A phase 3 trial of Trastuzumab pamirtecan run by DualityBio Inc. in her2-positive breast cancer, active.","summary":"A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer is a phase 3 interventional study registered as NCT06265428 by DualityBio Inc., with 228 participants enrolled, started 2024-01-29. Conditions listed: HER2-positive Breast Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06265428","url":"https://clinicaltrials.gov/study/NCT06265428"}],"tags":["ctgov-ingest"],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":["trastuzumab-pamirtecan"],"companies":["dualitybio"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06265428","phase":"3","setting":"A Phase III, Multicenter, Open-label, Randomized Study to Compare DB-1303 Versus T-DM1 in Patients With HER2-positive Unresectable/Metastatic Breast Cancer Who Have Been Treated With Trastuzumab and a Taxane (Dynasty-Breast01)","sponsor":"DualityBio Inc.","enrolled":228,"outcomes":[]},"route":"/trials/nct06265428/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"}],"drug":[{"id":"trastuzumab-pamirtecan","kind":"drug","name":"Trastuzumab pamirtecan","route":"/drugs/trastuzumab-pamirtecan/"}],"company":[{"id":"dualitybio","kind":"company","name":"Duality Biotherapeutics","route":"/companies/dualitybio/"}]}}